GlassScriptPhysician profile
Jennifer Olivier
NPI 1659699726
$23,673.49
in general payments reported to CMS, 2019-2025
30 companies · $17K in 2025
The $17K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $493 · 2021: $466 · 2022: $1,329 · 2023: $1,297 · 2024: $2,976 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $5,939 · Travel and Lodging: $1,890 · Education: $98.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,187.41 |
| Food and Beverage | $5,938.82 |
| Travel and Lodging | $1,889.56 |
| Education | $98.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16,964.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,835.10 | 2020-2025 | Fasenra, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $1,523.37 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,125.75 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Glaxosmithkline, LLC. | $814.12 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $332.37 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Ionis Pharmaceuticals, INC. | $166.89 | 2025 | Dawnzera |
| Grifols USA, LLC | $144.01 | 2020-2023 | Xembify |
| Novartis Pharmaceuticals Corporation | $126.94 | 2020-2025 | |
| Amgen INC. | $93.78 | 2022-2025 | Actimmune, Tezspire |
| Ars Pharmaceuticals Operations, INC. | $62.38 | 2025 | Neffy |
| Electromed, INC. | $53.39 | 2021-2025 | Smartvest |
| Genentech USA, INC. | $50.66 | 2019-2022 | |
| Shire North American Group INC | $49.13 | 2019 | |
| Verona Pharma, INC. | $46.91 | 2025 | Ohtuvayre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.72 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $30.81 | 2020 | |
| Lilly USA, LLC | $20.99 | 2024 | Ebglyss |
| Paratek Pharmaceuticals, INC. | $19.00 | 2025 | Xhance |
| Kedrion Biopharma, INC. | $18.32 | 2024 | Gammaked, Kedrab, Albuked |
| Arcutis Biotherapeutics, INC. | $18.28 | 2025 | Zoryve |
| Incyte Corporation | $17.82 | 2025 | Opzelura |
| Biocryst US Sales Co., LLC | $16.84 | 2024 | Orladeyo |
| Adma Biomanufacturing LLC | $16.41 | 2025 | |
| Phadia US INC. | $15.12 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.79 | 2020 | |
| Mylan Specialty L.P. | $14.76 | 2022 | |
| Kaleo, INC. | $12.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.99 | 2020 | |
| Bio Products Laboratory USA, INC. | $11.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Olivier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.